Page 71 - Haematologica May 2020

Long-term outcome of ATG & CSA ± G-CSF in SAA
References
1. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.
2. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal dis- eases of treated aplastic anemia. Semin Hematol. 2000;37(1):91-101.
3. Bacigalupo A. Antithymocyte globulin and cyclosporin: standard of care also for older patients with aplastic anemia. Haematologica. 2019;104(2):215-216.
4. Tisdale JF, Dunn DE, Geller N, et al. High- dose cyclophosphamide in severe aplastic anaemia: a randomised trial. Lancet. 2000;356(9241):1554-1559.
5. ScheinbergP,WuCO,NunezO,YoungNS. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol. 2009;144(2):206- 216.
6. Scheinberg P, Wu CO, Nunez O, et al. Treatment of severe aplastic anemia with a combination of horse antithymocyte glob- ulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica. 2009;94(3):348-354.
7. Cle DV, Atta EH, Dias DSP, et al. Rabbit antithymocyte globulin dose does not affect response or survival as first-line ther- apy for acquired aplastic anemia: a multi- center retrospective study. Ann Hematol. 2018;97(11):2039-2046.
8. Gluckman E, Rokicka-Milewska R, Hann I, et al. Results and follow-up of a phase III randomized study of recombinant human- granulocyte stimulating factor as support for immunosuppressive therapy in patients with severe aplastic anaemia. Br J Haematol. 2002;119(4):1075-1082.
9. Gordon-SmithEC,YandleA,MilneA,etal. Randomised placebo controlled study of RH-GM-CSF following ALG in the treat- ment of aplastic anaemia. Bone Marrow Transplant. 1991;7 Suppl 2:78-80.
10. Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using antithy- mocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96(6):2049-2054.
11. ShaoZ,ChuY,ZhangY,ChenG,ZhengY. Treatment of severe aplastic anemia with an immunosuppressive agent plus recombi- nant human granulocyte-macrophage colony-stimulating factor and erythropoi- etin. Am J Hematol. 1998;59(3):185-191.
12. Teramura M, Kimura A, Iwase S, et al. Treatment of severe aplastic anemia with
antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multi- center randomized study in Japan. Blood. 2007;110(6):1756-1761.
13. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. Exp Hematol. 2006;34(7):826-831.
ary to antithymocyte globulin treatment in severe aplastic anemia. Ann Pharmacother. 2007;41(5):895-898.
23. Gupta N, Mahapatra M, Rathi S, et al. Acute renal failure following antithymo- cyte globulin therapy for aplastic anaemia- report of two cases and review of literature. Ann Hematol. 2011;90(2):239-241.
24. Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11-19.
25. Dufour C, Svahn J, Bacigalupo A, Severe Aplastic Anemia-Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48(2):174-
14. Tichelli A, Schrezenmeier H, Socie G, et al.
A randomized controlled study in patients
with newly diagnosed severe aplastic ane-
mia receiving antithymocyte globulin
(ATG), cyclosporine, with or without G-
CSF: a study of the SAA Working Party of
the European Group for Blood and Marrow Transplantation. Blood. 2011;117(17):4434-
4441. 177.
15. Socie G, Mary JY, Schrezenmeier H, et al. Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2007;109 (7):2794-2796.
16. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immuno- suppressive therapy in children. Blood. 2002;100(3):786-790.
17. Locasciulli A, Bruno B, Rambaldi A, et al. Treatment of severe aplastic anemia with antilymphocyte globulin, cyclosporine and two different granulocyte colony-stimulat- ing factor regimens: a GITMO prospective randomized study. Haematologica. 2004;89(9):1054-1061.
18. Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90(3):1009- 1013.
19. Marsh JC, Zomas A, Hows JM, Chapple M, Gordon-Smith EC. Avascular necrosis after treatment of aplastic anaemia with anti- lymphocyte globulin and high-dose methylprednisolone. Br J Haematol. 1993;84(4):731-735.
20. ParkJ,JunJ,KimY,LeeJ,KimC,HahnS. Osteonecrosis of the hip in patients with aplastic anemia. J Korean Med Sci. 2002;17(6):806-810.
21. Socie G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM). Br J Haematol. 1997;97(4):865-870.
22. Barakat RK, Schmolck JP, Finkel KW, Foringer JR. Prolonged renal failure second-
26. Imashuku S, Hibi S, Nakajima F, et al. A review of 125 cases to determine the risk of myelodysplasia and leukemia in pediatric neutropenic patients after treatment with recombinant human granulocyte colony- stimulating factor. Blood. 1994;84(7):2380- 2381.
27. Socie G, Henry-Amar M, Bacigalupo A, et al. Malignant tumors occurring after treat- ment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med. 1993;329(16):1152-1157.
28. Giammarco S, Peffault de Latour R, Sica S, et al. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018;131(17):1989-1992.
29. Montori VM, Guyatt GH. Intention-to- treat principle. CMAJ. 2001;165(10):1339- 1341.
30. Rosenfeld S, Follmann D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289(9):1130-1135.
31. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540-1550.
32. Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018;2(21):3054-3062.
33. Dufour C, Veys P, Carraro E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idio- pathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4):585-594.
haematologica | 2020; 105(5)
1231